The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel
Abstract
Immunosuppressive tumor microenvironments (TMEs) create tremendous obstacles for an effective cancer therapy. Herein, we developed a melittin-RADA 32 hybrid peptide hydrogel loaded with doxorubicin (DOX) for a potent chemoimmunotherapy against melanoma through the active regulation of TMEs. The formed melittin-RADA 32 -DOX (MRD) hydrogel has an interweaving nanofiber structure and exhibits excellent biocompatibility, controlled drug release properties both in vitro and in vivo, and an enhanced killing effect to melanoma cells. A single-dose injection of MRD hydrogel retarded the growth of primary melanoma tumors by more than 95% due to loaded melittin and DOX, with concomitant recruitment of activated natural killer cells in the tumors. Furthermore, MRD hydrogel can activate dendritic cells of draining lymph nodes, specifically deplete M2-like tumor-associated macrophages (TAMs), and produce active, cytotoxic T cells to further defend the cells against remaining tumors, providing potent anticancer efficacy against subcutaneous and metastatic tumors in vivo . Multidose injection of MRD hydrogel eliminated 50% of the primary tumors and provided a strong immunological memory effect against tumor rechallenge after eradication of the initial tumors. Owing to its abilities to perform controlled drug release, regulate innate immune cells, deplete M2-like TAMs, direct anticancer and immune-stimulating capabilities, and reshape immunosuppressive TMEs, MRD hydrogel may serve as a powerful tool for anticancer applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“4 °C (data not shown); (6) versatile drug-loading capacity.”
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542
Cited by
Self-Healing Injectable Hydrogels for Tissue Regeneration
Bertsch, P., Diba, M., Mooney, D. J., & Leeuwenburgh, S. C. G. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00179 · Cited by 892
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Self-citationA review on recent advances in polymer and peptide hydrogels
Mondal, S., Das, S., & Nandi, A. K. (2020) · Soft Matter · doi:10.1039/c9sm02127b · Cited by 416
Zheng, J., Fan, R., Wu, H., Yao, H., Yan, Y., Liu, J., Ran, L., Sun, Z., Yi, L., Dang, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09601-3 · Cited by 414
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 328
Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
Pu, Y., & Ji, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874589 · Cited by 297
Liu, W.-L., Zou, M.-Z., Liu, T., Zeng, J.-Y., Li, X., Yu, W.-Y., Li, C.-X., Ye, J.-J., Song, W., Feng, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11157-1 · Cited by 272
Self-citationDuan, X., Chan, C., Han, W., Guo, N., Weichselbaum, R. R., & Lin, W. (2019) · Nature Communications · doi:10.1038/s41467-019-09221-x · Cited by 256
Injectable hydrogels as emerging drug-delivery platforms for tumor therapy
Cheng, Y., Zhang, H., Wei, H., & Yu, C.-Y. (2024) · Biomaterials Science · doi:10.1039/d3bm01840g · Cited by 65
Zhou, Y., Ye, T., Ye, C., Wan, C., Yuan, S., Liu, Y., Li, T., Jiang, F., Lovell, J. F., Jin, H., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.07.019 · Cited by 45
Self-citation
Metadata
- Authors
- Jin, H., Wan, C., Zou, Z., Zhao, G., Zhang, L., Geng, Y., Chen, T., Huang, A., Jiang, F., Feng, J.-P., Lovell, J. F., Chen, J., Wu, G., & Yang, K.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-03-20
- Volume
- 12
- Issue
- 4
- Pages
- 3295-3310
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2789332370
- Cited by
- 201
- References
- 9
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.